Phi Therapeutics


Phi Therapeutics
San Francisco, CA

Residents
Phi Therapeutics

We have developed a microbiome editing platform that allows us to perform both additive and subtractive functions on the microbiome. Using this approach, we can simply "weed out" the pathogen without disturbing the good microbiota, and replace it with a probiotic species. We are focused on chronic bacterial skin diseases, and our first indication is acne. Founded in 2014, we were awarded a NIH SBIR grant to develop our panel of candidates.